Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007;3(4):371-80.

Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy

Affiliations
Randomized Controlled Trial

Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy

Roland Asmar et al. Vasc Health Risk Manag. 2007.

Abstract

Background: Ambulatory blood pressure (BP) is more sensitive than office BP and is highly correlated with the left ventricular mass (LVM) of hypertensive patients with left ventricular hypertrophy (LVH).

Methods: In this prospectively designed ancillary study of the PICXEL trial, the effects of first-line combination perindopril/indapamide on ambulatory BP were compared with those of monotherapy with enalapril in 127 patients. Hypertensive patients with LVH received once daily either perindopril 2 mg/indapamide 0.625 mg (n = 65) or enalapril 10 mg (n = 62) for 52 weeks. Dose adjustments were allowed for uncontrolled BP. Twenty-four-hour ambulatory BP and echocardiographic parameters were measured at baseline, week 24, and week 52.

Results: At study end, both treatments significantly improved ambulatory BP compared with baseline (p < or = 0.01). Perindopril/indapamide treatment reduced 24-hour and daytime systolic BP (SBP) and pulse pressure (PP) significantly more than enalapril treatment (p < 0.01). No significant between-group differences were noted for diastolic BP (DBP) or for night-time measurements. Trough/peak ratios were higher with perindopril/indapamide than with enalapril (88.5 vs 65.8 for SBP and 86.7 vs 63.9 for DBP, respectively). The global smoothness index was higher with perindopril/indapamide than with enalapril (6.6 vs 5.2 for SBP and 5.6 vs 4.9 for DBP, respectively). With perindopril/indapamide treatment, LVM index was significantly reduced (-9.1 g/m2 from baseline; p vs baseline <0.001). More patients required dose increases with enalapril (87%) than with perindopril/indapamide (71%). No unusual safety elements were noted.

Conclusions: First-line perindopril/indapamide combination decreased ambulatory SBP and PP, and LVM more effectively than enalapril.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in ambulatory blood pressure after 52 weeks of treatment with perindopril/indapamide (n = 65) or enalapril (n = 62). A. Over 24 hours; B. Daytime; C. Night-time. Mean changes from baseline and standard deviations in parentheses are presented. *p vs baseline ≤0.01; **p vs baseline ≤0.001, p vs enalapril <0.01. Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure.
Figure 2
Figure 2
Variations in blood pressure over 24 hours in perindopril/indapamide (n = 65) and enalapril (n = 62). A. SBP; B. DBP; C. PP. Mean baseline and end-of-study ambulatory blood pressure calculated every 2 hours are plotted. Abbreviations: DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure.
Figure 3
Figure 3
Relationship between mean systolic blood pressure over 24 hours (mmHg) change (Wend − W0) and left ventricular mass index change in enalapril group (n = 62). ρ: Pearson correlation coefficient.
Figure 4
Figure 4
Relationship between mean SBP over 24 hours (mmHg) change (Wend − W0) and left ventricular mass index change (Wend − baseline) in perindopril/indapamide group (n = 65). ρ: Pearson correlation coefficient. Regression equation: LVMI change (WEND-Baseline) (ENA) = 6.8649 + 0.551855 *SBPMEAN24_CHANGE AT WEND

Similar articles

Cited by

References

    1. Meta-analysis suggests regression of left ventricular hypertrophy during antihypertensive treatment is linked to reduced risk of cardiovascular disease. Evid Based Cardiovasc Med. 2004;8:22–3. - PubMed
    1. Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens. 2005;18:1482–8. - PubMed
    1. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173–8. - PubMed
    1. Chalmers J, Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens. 2000;18:327–37. - PubMed
    1. Chanudet X, de Champvallins M. Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. Int J Clin Pract. 2001;55:233–9. - PubMed

Publication types

MeSH terms